Acute liver toxicity with ifosfamide in the treatment of sarcoma: a case report
Author Information
Author(s): Michelle CM Cheung, Robin L Jones, Ian Judson
Primary Institution: King's College Hospital, University of Washington, Royal Marsden Hospital
Hypothesis
This report aims to describe the serious liver toxicity associated with ifosfamide used in combination with doxorubicin.
Conclusion
The case highlights the potential for chemotherapy agents to cause rare and serious toxicities, necessitating vigilance from physicians.
Supporting Evidence
- The patient experienced a 250-fold increase in liver enzymes after chemotherapy.
- Supportive management and N-acetylcysteine treatment led to the reversal of liver toxicity.
- No liver toxicity was observed with subsequent chemotherapy cycles using doxorubicin alone.
Takeaway
A woman treated for cancer developed serious liver problems after taking a chemotherapy drug, but she got better after stopping the drug and receiving treatment.
Methodology
The patient was treated with ifosfamide and doxorubicin, and liver function was monitored after chemotherapy.
Limitations
The case report is based on a single patient, limiting generalizability.
Participant Demographics
61-year-old Caucasian woman with synovial sarcoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website